JIB-04 (NSC 693627) is primarily investigated for its potential in cancer research due to its ability to inhibit specific enzymes involved in tumor growth. It targets histone demethylases, which play a critical role in regulating gene expression, particularly in cancer cells. By blocking these enzymes, JIB-04 can disrupt cancer cell proliferation and survival. This makes it a promising candidate for studying epigenetic therapies in oncology. Additionally, its mechanism of action is being explored to understand its effects on other diseases influenced by epigenetic modifications. Research is ongoing to evaluate its efficacy and safety in preclinical models, with the aim of developing targeted treatments for various cancers.